US Court Grants MGI's Motion to Amend in Suit Against Illumina
PR88211
SAN FRANCISCO, Feb. 24, 2021 /PRNewswire=KYODO JBN/ --
A judge in the U.S. District Court for the Northern District of California has
granted MGI's motion for leave to amend to add a new inequitable conduct
defense of patent infringement lawsuit that Illumina filed against MGI in
February 2020 (Case No. 20-cv-01465).
During this patent prosecution process, MGI alleges that Illumina intentionally
withheld or failed to disclose a reference to a paper by Terez Kovacs and Laslo
Otvos ("Kovacs")[1]. MGI asserts that the Kovacs reference is material, both
because it discloses the same methodology that two of the inventors of the
7,541,444 patent used to convert nucleosides to nucleotides and also because it
provides a motivation for a person of ordinary skill in the art ("POSITA") to
convert nucleosides to nucleotides.
The Court's order concludes that MGI has acted with reasonable diligence,
amendment would not be unduly prejudicial to Illumina, and MGI's proposed
inequitable conduct claim is not clearly futile under the relevant pleading
standards. Accordingly, MGI's motion for leave to amend is granted.
MGI has already initiated an antitrust violation complaint towards Illumina in
the United States in Jan 2021. The complaint, filed recently in the California
Federal Court, pleads many instances of anticompetitive behavior including
asserting at least three patents against MGI companies in an unlawful and
fraudulent manner.
About MGI
MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling
effective and affordable healthcare solutions for all. Based on its proprietary
technology, MGI produces sequencing devices, equipment, consumables and
reagents to support life science research, medicine and healthcare. MGI's
multi-omics platforms include genetic sequencing and medical imaging. Providing
real-time, comprehensive, life-long solutions, its mission is to develop and
promote advanced life science tools for future healthcare. For more information
please visit https://en.mgi-tech.com. Or connect on social media:
https://twitter.com/MGI_BGI or https://cn.linkedin.com/company/mgi-bgi.
[1] The paper titled "Simple Synthesis of 5-Vinyl and 5-Ethynyl- 2'
Deoxyuridine- 5'- Triphosphates", was published in Tetrahedron Letters, Vol.
29, pp 4525-4528, 1988.
Source: MGI Tech Co., Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。